Lecture Series

For Closed Captions, start the video and click CC at the bottom.

The GSA KAER Toolkit for Brain Health

Jennifer Pettis, MS, RN, CNE

Acceptable Performance of Blood Biomarker Tests of Amyloid Pathology - Recommendations from the Global CEO Initiative on Alzheimer's Disease

Suzanne E. Schindler, MD, PhD

5/16/2024 FDA Guidance: Early Alzheimer's Disease: Developing Drugs for Treatment

Nadezda Radoja, PhD

5/16/2024 Harding Center for Risk Literacy: Study of How People Behave in Situations of Risk and Uncertainty 

Felix G. Rebitschek, PhD

A Delphi Study to Develop Stakeholder Consensus Regarding Sharing Individual Research Results in ADRD Research

Lauren Sankary, JD, MA

Alzheimer's Clinical Trial Consortium Research Participant Advisory Board

Sarah Walter, MSc

Obstacles to Equitable and Timely Access to New Alzheimer Disease Diagnostics and Treatments

Suzanne E. Schindler, MD, PhD

Testing the Feasibility and Acceptability of Using Plasma Biomarkers for Diagnosing Alzheimer's Disease in Primary Care

Nicole R. Fowler, PhD, M

Davos Alzheimer's Collaborative

Tim MacLeod, PhD

The Global CEO Initiative on Alzheimer's Disease

Emily Scholler, MPH

The Intersection of Direct-to-Consumer Testing & Dementia

Jalayne Arias, JD, MA

Brain Watch Coalition

Brittany Cassin, MBA and Ara S. Khachaturian, Ph.D.

The Wild West of Alzheimer Disease Blood Tests

Suzanne E. Schindler, MD, PhD

Update: FDA will increase control over lab developed tests such as the ones described here

Quest Alzheimer's Blood Test No Longer Marketed Directly to Patients

Bio-Hermes-001 and Biomarker Assessment Against a Gold Standard

Suzanne Hendrix, PhD & Jenn Gaudioso, BS

Lecanemab for Early Alzheimer's Disease:

ICER's Review and Policy Implications

Grace Lin, MD

Preparing the Healthcare System to Support Timely Diagnosis and Treatment for AD

Pei-Jung (Paige) Lin, PhD

Pathways to Well-Being with Dementia

Rev. Dr. Cynthia Huling Hummel

                          Regulatory Landscape for Biomarkers Development:                         

Relevance for AD/ADRD Research and Therapy Development

Nadezda Radoja, PhD 

Global CEO Initiative on AD Blood-Based Biomarker Working Group 

Katie Partrick, PhD 

The GSA KAER Toolkit for Primary Care Teams

Karen K. Tracy, BS and Jennifer L. Pettis, MS

Sequential Administration of DIGItal Testing in the Primary Care Setting to Screen for Cognitive Impairment Followed by Blood Based Biomarkers to Assist with Timely Detection and Accurate Diagnosis of ALzheimer's Disease at Indiana University (IU) and IU Health (IUH)

Nicole Fowler, PhD 

Considering a Framework for Return of Individual Research Results

Barbara E. Bierer, MD

Blood Tests for Alzheimer's Disease

Thomas Karikari, PhD

Considerations Regarding a Diagnosis of AD Based on Biomarkers

Jetske van der Schaar, MS

FDA Market Authorization of the Lumipulse® G β-Amyloid Ratio (1-42/1-40) Test

Rianne Esquivel, PhD

Overview: The Alzheimer's Disease Neuroimaging Initiative (ADNI). Plans For ADNI4 Improving Generalizability by Increasing Diversity

Michael Weiner, MD

Development of Algorithm to Calculate 5 Year Absolute Risk of AD

Sarah Hartz, MD, PhD and Jessica Mozersky, PhD

Sharing Biomarker Results with Cognitively Healthy Research Participants

Lindsay Clark, PhD

Update on Status of Blood-Based Markers for Alzheimer's Disease: 

Readiness for Clinical Use 

Michelle M. Mielke, PhD

Biofluid Biomarkers of Neuropsychiatric Symptoms in Dementia with 

Lewy Bodies & Alzheimer's Disease

Fabricio Oliveira, MD, PhD 

Dementia in the Borderlands

Gladys Maestre, MD, PhD

Aducanumab: Where do we go from here?

Joshua Grill, PhD

The Next Steps Towards Precision Medicine in Parkinson's Disease

Ron Alcalay, MD

Communicating 5 Year Risk of AD Dementia Based on Multiple Research Results to a Longitudinal Cohort of Healthy Older Adults

Jessica Mozersky, PhD

Overcoming Stigma

Rev. Dr. Cynthia Huling Hummel

Results from the Study of Knowledge and Reactions to Amyloid Testing (SOKRATES)

Emily A. Largent, JD, PhD 

The First Blood Test for Alzheimer Disease is Now Available for Clinical Use

Suzanne Schindler, MD

Utilization of Cerebrospinal Fluid Biomarkers for the Detection 

of Alzheimer's Disease in Mild Cognitive Impairment 

and Subjective Cognitive Decline in Routine Clinical Care in Germany

Anja Schneider, MD

Deepening Stakeholder Engagement through attendance of 

a virtual Scientific Conference

Sarah Walter, MSc  

Asian Cohort for Alzheimer's Disease Study

Li-San Wang, PhD 

 Legal Protections and Vulnerabilities from Genetic and Biomarkers

Jalayne Arias, JD

Return of Genomic Results in All of Us

Robert C. Green, MD

Ethics in the European Prevention of Alzheimer's Dementia (EPAD) project

Richard Milne, PhD 

MRI Face Recognition and De-Identification

Christopher Schwartz, PhD 

COVID-19 Issues

Robyn S. Shapiro, JD

Effects of Advances in Biomarker-Based Diagnosis and Disease-Modifying Treatment on Alzheimer's Disease Stigma 

Shana D. Stites, PsyD

VISN 17 Center of Excellence for Research on Returning War Veterans

Laura Zambrano-Vazquez, PhD

Upcoming Speakers